Pfizer and Thermo Fisher Scientific partner to bring accessible NGS-based testing to international markets
The collaboration between the pharmaceutical giant and scientific technology provider will aim to bring rapid and localised services to areas around the globe that lack affordable advanced genomic testing for breast and lung cancer.
Pfizer and Thermo Fisher Scientific have entered into a partnership agreement for the expansion of access to next-generation sequencing (NGS)-based testing for patients with lung and breast cancer. With local access set to increase in 30 countries across Latin America, Africa, the Middle East, and Asia, the collaboration hopes to bring advanced genomic testing to previously inaccessible regions of the globe.
As the leading cause of death around the world and nearly 10 million deaths attributed to the disease in 2020, breast and lung cancer are the leading types of diagnosed cancer. The global burden, both economic and social, is expected to reach 27.5 million new cases in 2040 and 16.3 million deaths. While gene testing has historically been used to match patients with the appropriate targeted therapies, the standard single-gene biomarker testing can be time-consuming, with sequential tests and enough tissue and organic material to run each test. NGS technology provides healthcare professionals and clinical trial teams with rapid genomic information to make informed precision oncology treatment decisions. Some decisions can affect the survival rate and time-to-next treatment, so it is crucial to identify actionable treatments from rapid molecular testing to make informed treatment decisions.
Gianluca Pettiti, Executive VP at Thermo Fisher Scientific, commented: “Anyone facing a cancer diagnosis should have access to cutting-edge testing that can match them with an appropriate, optimised treatment plan and better inform their care. Today, we aim to bring rapid NGS testing to an increased number of decentralised labs, closer to where patients are treated. We are moving one step closer to delivering precision insights to underserved patients so they can receive a more tailored path for their care no matter where they are in the world.”
The agreement will see Thermo Fisher identifying local labs that can house the organisation’s NGS technology with the necessary infrastructure, skilled staff and staff training, and quality control methods that meet industry standards for NGS testing for breast and lung cancer. Pfizer, under the collaboration, will be responsible for exploring different avenues of affordable patient access to NGS testing for breast and lung cancer. Promotion of healthcare provider awareness regarding advanced testing and the need for such tests will be a main priority for Pfizer, and the partnership will continuously evaluate new opportunities to expand both geographically and to testing for other types of cancers.
Pfizer’s Global President of Emerging Markets Nick Lagunowich stated: “The more we understand the complex science behind cancer, the better we can treat it. Our experience has taught us that cancer cannot always be treated with a broad brush and often requires an individualised approach based on precise disease characteristics. In many parts of the world, access to next-generation sequencing may be limited or unaffordable for cancer patients. This program aims to improve their treatment journey and help increase their chances for improved outcomes.”
Source: Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next-Generation Sequencing-Based Testing for Cancer Patients in International Markets [Accessed May 10, 2023] https://www.businesswire.com/news/home/20230509005516/en/Thermo-Fisher-Scientific-Pfizer-Partner-to-Expand-Localized-Access-to-Next-Generation-Sequencing-Based-Testing-for-Cancer-Patients-in-International-Markets%C2%A0
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance